FDA Cites Gopaldas Visram & Co., Ltd. in 2026-06-02 Warning Letter — CGMP/OTC Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/OTC Finished Pharmaceuticals/Adulterated
TL;DR
Here's the summary: FDA's Center for Drug Evaluation and Research (CDER) issued a Warning Letter to Gopaldas Visram & Co., Ltd. on 2026-06-02 regarding CGMP/OTC Finished Pharmaceuticals/Adulterated. The letter references 21 CFR 211.160(b), 21 CFR 211.192, 21 CFR 211.22. The verbatim letter is published on fda.gov.
Argus analysis
Gopaldas Visram & Co., Ltd. received a Warning Letter from FDA's Center for Drug Evaluation and Research (CDER), dated 2026-06-02, regarding CGMP/OTC Finished Pharmaceuticals/Adulterated. The letter follows an FDA inspection and is classified by Argus HQ as critical severity, consistent with Current Good Manufacturing Practice violations under 21 CFR Part 211 (drugs) or Part 600 (biologics).
The published letter cites 21 CFR 211.160(b), 21 CFR 211.192, 21 CFR 211.22. Warning Letters citing these sections generally concern Current Good Manufacturing Practice violations under 21 CFR Part 211 (drugs) or Part 600 (biologics), typically covering component testing, cleaning validation, laboratory controls, or investigation of out-of-specification results. The full citation language and supporting observations are in the verbatim letter linked below — Argus HQ does not add citations beyond what FDA published.
FDA Warning Letters carry a 15-business-day response window for the recipient to detail corrective actions. Peer compliance teams in the same product category typically use a letter like this one as an external audit trigger, checking whether their own quality system has documented coverage for the cited sections and whether their CAPA log would withstand the same line of inspection questioning.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Gopaldas Visram & Co., Ltd. MARCS-CMS 721755 — June 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS Reference #: 320-26-86 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Mukund V. Thakker Recipient Title Director Gopaldas Visram & Co., Ltd. Plot No. A /327, TTC Industrial Area, M.I.D.C., Mahape Navi Mumbai 400710 Maharashtra India Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-86 June 2, 2026 Dear Mr. Thakker: Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 14, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Gopaldas Visram & Co., Ltd., FEI 3009565091, at Plot No. A /327, TTC Industrial Area, M.I.D.C., Mahape, Navi Mumbai, Maharashtra. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)). Following review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following: 1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity. Your firm also failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.22 and 21 CFR 211.192). Your firm manufactures multiple OTC (b)(4) drug products labeled and formulated to contain active ingredients such as (b)(4) . These drug products are also labeled and formulated to contain the inactive ingredient talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled. 1,2 Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of (b)(4) containing talc in the (b)(4) area and the incidence of (b)(4) , potentially linked to asbestos contamination of the talc. 3 The (b)(4) you produce can …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Gopaldas Visram & Co., Ltd. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Gopaldas Visram & Co., Ltd. as of 2026-06-09. Argus ingests new FDA enforcement records daily.
- What FDA violations was Gopaldas Visram & Co., Ltd. cited for?
- The FDA Warning Letter to Gopaldas Visram & Co., Ltd. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/OTC Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Gopaldas Visram & Co., Ltd.?
- FDA issued the letter (MARCS-CMS 721755) on 2026-06-02 and posted it publicly on fda.gov on 2026-06-09.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Gopaldas Visram & Co., Ltd. in 2026-06-02 Warning Letter — CGMP/OTC Finished Pharmaceuticals/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-gopaldas-visram-and-co-ltd-2026-06-02-cgmp
"FDA Cites Gopaldas Visram & Co., Ltd. in 2026-06-02 Warning Letter — CGMP/OTC Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-gopaldas-visram-and-co-ltd-2026-06-02-cgmp.
Argus HQ Research. "FDA Cites Gopaldas Visram & Co., Ltd. in 2026-06-02 Warning Letter — CGMP/OTC Finished Pharmaceuticals/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-gopaldas-visram-and-co-ltd-2026-06-02-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_gopaldas_visram_and_co_ltd_2026_06_02_cgmp_2026,
title = {FDA Cites Gopaldas Visram & Co., Ltd. in 2026-06-02 Warning Letter — CGMP/OTC Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-gopaldas-visram-and-co-ltd-2026-06-02-cgmp},
note = {Accessed: July 13, 2026}
}